1,1-Dimethylethyl 7-[(3S)-3-amino-2-oxo-1-pyrrolidinyl]-6-fluoro-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate | 939043-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1,1-Dimethylethyl 7-[(3S)-3-amino-2-oxo-1-pyrrolidinyl]-6-fluoro-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate
• 英文别名: tert-butyl 7-[(3S)-3-amino-2-oxopyrrolidin-1-yl]-6-fluoro-1,3,4,5-tetrahydro-2-benzazepine-2-carboxylate
• CAS: 939043-62-6
• 化学式: C₁₉H₂₆FN₃O₃
• 分子量: 363.432
• InChiKey: RWACCFVNEOZQCJ-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,1-Dimethylethyl 7-[(3S)-3-amino-2-oxo-1-pyrrolidinyl]-6-fluoro-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate 在 吡啶 、 盐酸 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 2-(5-chlorothiophen-2-yl)-N-[(3S)-1-(6-fluoro-2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)-2-oxopyrrolidin-3-yl]ethenesulfonamide
  参考文献：
  名称：

  The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs

  摘要：

  The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.129
• 作为产物：
  描述：

  2,3-二氟溴苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 甲烷磺酸 、 四磷十氧化物 、 20 % Pd(OH)2/C 、 硼烷 、 盐酸羟胺 、 ammonium acetate 、 氨 、 氢气 、 caesium carbonate 、 二甲胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 pyridinium chlorochromate 、 碘甲烷 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 20.0~160.0 ℃ 、344.75 kPa 条件下， 生成 1,1-Dimethylethyl 7-[(3S)-3-amino-2-oxo-1-pyrrolidinyl]-6-fluoro-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate
  参考文献：
  名称：

  The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs

  摘要：

  The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.129

文献信息

• 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors
  申请人：Camus Laure

  公开号：US20080306045A1

  公开（公告）日：2008-12-11

  The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  该发明涉及式(I)的化学实体和/或其药用可接受衍生物。该发明还涉及制备式(I)化合物的方法，含有式(I)化合物的药物组合物以及在医学中使用式(I)化合物，特别是在改善适用于Xa因子抑制剂的临床病况中的使用。
• The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
  作者：Nigel S. Watson、Carl Adams、David Belton、David Brown、Cynthia L. Burns-Kurtis、Laiq Chaudry、Chuen Chan、Máire A. Convery、David E. Davies、Anne M. Exall、John D. Harling、Stephanie Irvine、Wendy R. Irving、Savvas Kleanthous、Iain M. McLay、Anthony J. Pateman、Angela N. Patikis、Theresa J. Roethke、Stefan Senger、Gary J. Stelman、John R. Toomey、Robert I. West、Caroline Whittaker、Ping Zhou、Robert J. Young

  DOI：10.1016/j.bmcl.2011.01.129

  日期：2011.3

  The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.